trial · primary record
IV normal saline
Systemic Inflammation
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 45 |
| Primary completion | 2026-12-15 |
| Primary endpoint | Effects of intravenous immunoglobulin therapy |
| Registry ID | NCT05350774 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:37.312Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05350774
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.